American College Of Rheumatology 2008 Annual Meeting Highlights

Rheumatoid Arthritis Patients do Worse After a Heart Attack Following a heart attack, people with rheumatoid arthritis (RA) suffer greater heart-related complications, including an increased risk for dying, when compared to other heart attack patients, according to research presented at the American College of Rheumatology Annual Scientific Meeting in San Francisco.

Increasing Incidence Of Rheumatoid Arthritis In Women

After four decades on the decline, rheumatoid arthritis is on the upswing among women in the United States. That's the finding presented by Mayo Clinic investigators at the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals in San Francisco. "This is a significant finding and an indicator that more research needs to be done to better understand the causes and treatment of this devastating disease," says Sherine Gabriel, M.D.

Psoriatic Arthritis: First International Guidelines For Treatment

Rheumatologists, dermatologists, and patient advocates have come together to publish the first-ever international guidelines for the treatment of psoriatic arthritis, a disease that mainly affects people who have psoriasis but also some people without it. The guidelines by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) were presented at the annual meeting of the American College of Rheumatology. The group was headed by Christopher Ritchlin, M.

Pfizer To Present Data On New Approaches To Pain And Inflammation Treatment At ACR Meeting

Pfizer will present data on three investigational compounds that represent potential new mechanisms for targeting pain and inflammation. These data will highlight tanezumab, a molecule designed to target nerve growth factor, a key pain mediator; CP-690,550, a JAK-inhibitor that suppresses immune-related inflammatory response; and esreboxetine, a highly-selective norepinephrine reuptake inhibitor which plays a role in controlling the activity of this important neurotransmitter.

Study Shows ENBREL(R) (etanercept) More Effective Than A DMARD In The Treatment Of Symptoms Of Ankylosing Spondylitis Patients

New safety and efficacy data for active ankylosing spondylitis (AS) patients treated with ENBREL(R) (etanercept) were presented at the American College of Rheumatology (ACR) Scientific Meeting, 24-29 October, in San Francisco, CA: (1),(2) - As discussed in an oral pr

Traditional Cardiovascular Risk Factors Increase, Treatments Reduce Heart Attack Risk In People With Rheumatoid Arthritis

Age, sex and traditional risk factors - such as hypertension, diabetes, smoking, and body mass - are more important predictors of heart attack in patients with rheumatoid arthritis than the use of certain medications that have been considered the link between the two and lipid-lowering medications may actually reduce this risk, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in San Francisco, Calif.

Rheumatoid Arthritis On The Rise Among American Women

Scientists presenting findings of their research at a conference in the United States at the weekend said they found evidence that after four decades of decline, rheumatoid arthritis was on the rise among American women.